Patents Examined by Jeffrey S. Parkin
  • Patent number: 11813325
    Abstract: Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: November 14, 2023
    Assignee: Her Majesty the Queen in the Right of Canada as Represented by the Minister of Health
    Inventor: Ma Luo
  • Patent number: 11801294
    Abstract: The invention relates to arenaviruses for use in the treatment and/or prevention of tumors and also a method for preparing arenaviruses with (improved) tumor-regressive properties.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: October 31, 2023
    Assignee: ABALOS THERAPEUTICS GMBH
    Inventors: Karl Sebastian Lang, Halime Kalkavan
  • Patent number: 11767347
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 26, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • Patent number: 11754565
    Abstract: The present invention relates to a method of quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 12, 2023
    Assignee: MOCKV SOLUTIONS LLC
    Inventors: David Cetlin, Arun Dhar
  • Patent number: 11739347
    Abstract: The present disclosure relates to a mammalian cell line for producing adeno-associated virus (AAV), suitably including nucleic acids encoding helper genes and AAV genes, under the control of derepressible promoters. The disclosure also relates to isolated nucleic acid molecules that encode such genes, as well as methods of using the mammalian cells for producing AAVs.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 29, 2023
    Assignee: LONZA WALKERVILLE, INC.
    Inventors: Bingnan Gu, Caitlin M. Guenther, Anandita Seth
  • Patent number: 11732010
    Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: August 22, 2023
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
  • Patent number: 11732244
    Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: August 22, 2023
    Assignees: THE JOHNS HOPKINS UNIVERSITY, LIFE TECHNOLOGIES CORPORATION
    Inventors: Brian Agnew, David Graham
  • Patent number: 11730813
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: August 22, 2023
    Assignees: HUMABS BIOMED SA, INSTITUT PASTEUR
    Inventors: Davide Corti, Hervé Bourhy
  • Patent number: 11723977
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: August 15, 2023
    Assignees: Institut Pasteur, Humabs Biomed SA
    Inventors: Davide Corti, Hervé Bourhy
  • Patent number: 11725044
    Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: August 15, 2023
    Assignee: Xenothera
    Inventors: Odile Duvaux, Jean-Paul Soulillou
  • Patent number: 11723968
    Abstract: The present invention describes specific engineering of the hantavirus spike proteins with modifications to stabilize (Gn/Gc)n heterodimer contacts and/or Gc homodimer contacts and/or Gn/Gn oligomer contacts on the spike with the purpose of using them as immunogens in next-generation vaccine design. Said spike proteins have been covalently stabilized by at least one disulphide inter-chain bond between Gn/Gc heterodimers and/or between Gc homodimers and/or between Gn homo-oligomers as they are presented at the surface of infectious virions. It also involves spike stabilization by introduction of cavity-filling amino acids with a bulky side chain at the above-mentioned contacts.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 15, 2023
    Assignees: FUNDACION CIENCIA PARA LA VIDA, INSTITUT PASTEUR
    Inventors: Nicole Tischler, Eduardo Andrés Bignon Silva, Félix Augusto Rey, Pablo Guardado Calvo
  • Patent number: 11719695
    Abstract: The purpose of the present invention is to: provide an agent that effectively suppresses inhibition of antigen-antibody reaction in an immunoassay using a sample containing a body fluid, in particular, a component derived from a biological mucosal membrane, such as saliva; and to suppress false positive and false negative results in the immunoassay. The present invention provides an agent for suppressing inhibition of immune reaction, characterized in that the agent comprises a compound of the following (1) or (2): (1) Sulfonic acid compound of the formula R1—SO3H or a salt thereof. (In the formula, R1 is selected from the group consisting of: a straight-chain C5-C30 alkyl group; a straight-chain C1-C30 alkyl group substituted with an aryl group having at least one straight-chain C5-C30 alkyl group; and an aryl group having at least one straight-chain C5-C30 alkyl group. These groups may include a substituent group); and (2) Quaternary ammonium ion of the formula N+—R2R3R4R5 or a salt thereof.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: August 8, 2023
    Assignees: NH Foods Ltd, National Agriculture and Food Research Organization
    Inventors: Eri Takeuchi, Kana Urayama, Takashi Matsumoto, Kazuki Morioka, Makoto Yamakawa, Kazuo Yoshida, Toru Kanno, Katsuhiko Fukai
  • Patent number: 11702674
    Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: July 18, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
  • Patent number: 11701418
    Abstract: The compositions and methods are described for generating an immune response to a hemorrhagic fever virus such as ebolavirus, Marburgvirus, or arenavirus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Ebolavirus (such as a member of species Zaire ebolavirus), a member of genus Marburgvirus (such as a member of species Marburg marburgvirus), or a member of genus Arenavirus (such as a member of species Lassa virus) in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by ebolavirus, Marburgvirus, or arenavirus.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: July 18, 2023
    Assignee: Geovax, Inc.
    Inventors: Harriet Latham Robinson, Arban Domi, Michael Salant Hellerstein
  • Patent number: 11684668
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: June 27, 2023
    Assignee: NantCell, Inc.
    Inventor: Kayvan Niazi
  • Patent number: 11666651
    Abstract: The present invention relates to immunogenic therapies for the treatment or prevention of a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: June 6, 2023
    Assignee: AELIX Therapeutics, S.L.
    Inventors: Christian Brander, Beatriz Mothe-Pujadas
  • Patent number: 11649511
    Abstract: The present invention provides a novel coronavirus duplex detection kit. Specifically, the present invention discloses a kit and method for multiplex detection of novel coronavirus 2019-nCoV nucleic acid, which can simultaneously detect two nucleic acid targets of the novel coronavirus 2019-nCoV and possess extremely high sensitivity and specificity, and significantly improve the accuracy of virus identification.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: May 16, 2023
    Assignee: DAAN GENE CO., LTD.
    Inventors: Xiwen Jiang, Jian Fan, Hailong Peng, Rongyu Peng
  • Patent number: 11649276
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: May 16, 2023
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11638750
    Abstract: The compositions and methods are described for generating an immune response to a flavivirus such as Zika virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Flavivirus (such as a member of species Zika virus), in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by Flavivirus.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: May 2, 2023
    Assignee: Geovax, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Patent number: 11638751
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: May 2, 2023
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet